Autologous Stem Cell Transplantation in Adult Patients with Intermediate-Risk Acute Myeloid Leukemia in First Complete Remission and No Detectable Minimal Residual Disease. A Comparative Retrospective Study with Haploidentical Transplants of the Global Committee and the ALWP of the EBMT

Researchers compared the outcome post autologous stem cell transplantation or haploidentical transplants in patients with intermediate-risk acute myeloid leukemia achieving first complete remission and measurable residual disease negativity at pretransplant in the period from 2010 to 2021.